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Nonimmunoglobulin C3 activating factor in
membranoproliferative gb merubonephritis
BRUCE G. BARTLOW, JIMMY L. ROBERTS, and EDMUND J. LEWIS
Section of Nephrology, Department of Medicine, Rush Medical College, Chicago, Illinois
Nonimmunoglobulin C3 activating factor in membranoprolif-
erative glomerulonephritis. Material isolated by cryoprecipita-
tion from the serum of a patient with membranoproliferative gb-
merulonephritis exhibited alternative complement pathway C3-
splitting activity associated with a nonimmunoglobulin y-migrat-
ing protein. The cryoprecipitate required factor B and magne-
sium ions, but not Cl, C2, or calcium ions for activity. Anti-
serum produced against the cryoprecipitate recognized a pre-
viously unidentified y-migrating material, as well as $1H globulin
(C3b inactivator-accelerator), and K light chains. Immunoglobu-
lin (Ig) U was present in trace quantities. Immunoadsorption
with antisera to human y heavy chains or K light chains did not
alter C3 activation by the resolubilized material. The y-migrating
material, which appears to be an altered form of a normal 02
protein, retains its C3 splitting property when separated from
f31H and IgG by sucrose density ultracentrifugation. Antisera
monospecific to /3H and to the y-migrating material each pro-
duced intense glomerular immunofluorescence in the patient's
renal biopsy in a pattern similar to that of anti-C3. No glomerular
staining occurred with antihuman IgG, M, A, E, Clq, C4, or C2.
It is proposed that interaction between this protein and 13I11 in
the circulation and in the glomerulus could block f3,H-dependent
decay-dissociation of C3 convertases, resulting in unregulated al-
ternative complement pathway C3 activation and complement-
mediated glomerular damage.
Un facteur nonimmunoglobulinique activateur de C3 dans Ia
glomérulonéphrite membranoproliférative. Le materiel isolé par
cryoprécipitation du serum d'un malade atteint de glomdrulon-
ëphrite membranoproliférative posséde une activité de clivage
du C3 par Ia voie alterne associée a une proteine nonimmu-
noglobulinique migrant avec les y. L'activitë du cryoprëcipité
requiert le facteur B et ions de magnesium mais pas Cl, C2, ou
ions de calcium. L'antisérum produit contre le cryoprécipité re-
connait on materiel jusque là nonidentifié migrant avec les y, de
même que la f31H globuline (C3b inactivateur-accélérateur), et
les chaines legeres K. L'immunoglobuline (Ig)G est prdsente a
l'dtat de traces. L'immunoadsorption avec un antiserum contre
les chaines lourdes y ou les chaines legeres K ne modifie pas
l'activation de C3 par le materiel resolubilisé. Le materiel mi-
grant avec les y, qui paraIt être une forme modifiée d'une pro-
téine normale 02, conserve ses propriétés de clivage de C3
quand ii est séparé de B1H et de IgG par ultracentrifugation sur
gradient de sucrose. Les antisérums monospécifiques de /31H et
du materiel migrant avec les y produisent tous deux une immuno-
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fluorescence glomerulaire intense sur Ia biopsie rénale do malade,
avec un aspect semblable a celui de l'anti-C3. II n'y a pas de
fluorescence avec les anti-IgG, M, A, E, Clq, C4, ou C2 humains.
II est propose que l'interaction entre cette protéine et 131H dans
la circulation et dans les glomerules puisse bloquer Ia dissociation
3,H dépendante des C3 convertases avec pour resultat one acti-
vation nonregulee de C3 par Ia voie alterne et des lesions
glomérulaires dues au complement.
Patients with membranoproliferative glomerulo-
nephritis (MPGN) frequently have low serum levels
of the third component of complement (C3). This
has been attributed to activation of the alternative
complement pathway by a serum protein, designat-
ed C3 nephritic factor (C3NeF) [1—3]. Current evi-
dence suggests that the component of nephritic
serum which possesses C3NeF activity behaves as
an immunoglobulin (Ig) G on electrophoresis, mo-
lecular sieve and ion exchange chromatography,
and sucrose density ultracentrifugation [4-81. Re-
cently, immunoadsorption studies have been used
to identify various patients' C3NeFs as IgG of re-
stricted, though variable, light and heavy chain
composition and electrophoretic mobility [6-81. It
has been suggested that, in serum, C3NeF may sta-
bilize the alternative complement pathway C3 con-
vertase, C3bBb, by binding to it as a con-
formational antibody [61.
We have studied a patient with membranoprolif-
eration glomerulonephritis whose serum had nor-
mal concentrations ofClq, C4, and C2 and low con-
centrations of C3, factor B (C3 proactivator,
C3PA), and properdin (P). We have isolated a
cryoprecipitate from this patient's serum which is
capable of cleaving C3 via the alternative com-
plement pathway; this material fulfills functional
criteria for C3NeF, including dependence upon
magnesium ions and factor B, but not calcium ions,
Cl, or C2 [9, 10]. We have studied this patient's
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serum, plasma, and renal biopsy tissue to (1) define
the components present in the cryoprecipitate, (2)
determine the functional properties of the material
and its components, and (3) ascertain whether the
components were demonstrable on immuno-
pathologic examination of the renal biopsy.
Methods
Blood samples from a 42-year-old female patient
were collected and processed for the presence of
cryoprecipitable material according to previously
published techniques [11]. Briefly, after being
clotted at 37° C for 4 hours and centrifuging, sera
samples containing 0.01% sodium azide were kept
at 4° C for 5 days and centrifuged at x 1000g for 30
mm. The supernatant serum was then removed, and
cryoprecipitate was washed three times in 50 vol-
umes of cold 0.1 M phosphate-buffered saline (PBS)
(pH, 7.4) with azide. The precipitate was resus-
pended in one tenth of the original serum volume of
PBS with azide. Precipitate was solubilized by in-
cubation for 1 hour at 37° C before immunologic or
functional studies were performed.
Complement activation was assayed qualitatively
as a change in the electrophoretic mobility of C3 to
the C3c position, and the /3-globulin factor B to a y
(Bb, C3 activator, C3A) position [3, 9]. Fifty micro-
liters of test material was mixed with 100 d of fresh
normal human serum (NHS) and 10 d of either 0.05
M magnesium-EGTA in 0.9% saline, 0.1 M EDTA in
0.9% saline, or 0.9% saline. Sera incubated with
PBS or zymosan, 10 mg/mI, were used as controls.
Reaction mixtures were incubated for up to 60 mm
at 37° C with shaking. Convertase formation was
stopped at 15 mm by the addition of 0.1 volume/vol-
ume (vollvol) 0.4 M EDTA (pH, 7.4), and the reac-
tion was allowed to proceed an additional 45 mm
[3]. Immunoelectrophoresis (IEP) of reaction mix-
ture aliquots was performed in 1.0% agar or 1.5%
agarose with veronal-buffered saline (VBS) (I =
0.05; pH, 8.6) with 0.01 M EDTA, using antisera
specific to C3/C3c and factor B, respectively [121.
Activation of C3 was measured quantitatively by
the ability of test substance to induce a loss of C3
native-(B-) antigen in NHS [3]. Reaction mixtures
with the same concentrations and conditions as
stated above for the qualitative assay were analyzed
for C3 native-antigen content before and after in-
cubation. Radial immunodiffusion (RID) was per-
formed in 2% agarose with glycine buffer (pH, 7.6)
with 0.04 NI and 0.1 vollvol goat antiserum to
human C3 B-antigen' [13].
The functional stability of the cryoprecipitate was
tested by incubation at 54°, 56°, and 60° C for 30 mm
[3, 10]. To determine whether the genesis or func-
tion of our patient's C3 activating factor (C3AF)
was due to in vitro incubation in the cold, sera and
plasma samples were studied as follows: Aliquots
were incubated at 37° C and at 4° C for 16 hours and
compared with fresh 37° C serum for C3 splitting
activity and changes in the quantity or elec-
trophoretic mobility of C3/C3c and factor B. The
levels of C3 native-antigen were also assayed before
and after the incubations [14, 15].
To test the dependence of the material on certain
serum complement components, we used the fol-
lowing reagents: (1) NHS was depleted of factor B
by heating at 50° C for 30 mm. (2) The classical
complement sequence was blocked by (a) addition
to NHS of magnesium-EGTA to 0.005 NI, or by use
of(b) C2-deficient human serum or (c) human serum
depleted of Cl [10, 161.
Immunoelectrophoresis and Ouchterlony double-
diffusion to identify antigenic determinants in the
cryoprecipitate were carried out in 1.5% agarose
with VBS (I = 0.05; pH, 8.6) using antiwhole hu-
man antiserum and antisera monospecific to human
IgG2'3'4, 1gM2'3, IgA3'5, IgE2, C1q4, C1s3, Cl este-
rase inhibitor3, C42, C2', C3/C3c2, C3d1, CS2, P4,
factor B"4, C3b inactivator (C3bINA, KAF)1, /3,H
globulin (C3b inactivator-accelerator, AC3bINA)',
K light chains3'4, A light chains3, fibrinogen2, a-2-
macroglobulin3, albumin2, C-reactive protein3,
transferrin8, /3-microglobulin7, /32-glycoprotein J3,
f32-glycoprotein III, /3-lipoprotein3, and hemo-
pexin. Immunoelectrophoresis was performed at
room temperature at 7 V/cm for 1 hour. To identify
components of the cryoprecipitate which might
form nonprecipitating complexes with specific anti-
sera, we performed augmented double-diffusion and
IEP in 1.2% agarose, VBS (I = 0.05, pH = 8.6)
with 0.01 M EDTA and 2.5% polyethylene glycol
(PEG) [17]. Trace antigenic components were
Antiserum provided by Ms. Judith Forristal and Dr. Clark D.
West, Children's Hospital Research Foundation, Cincinnati,
Ohio.
2 Meloy Laboratories, Springfield, Virginia.
Behring Diagnostics, Sommerville, New Jersey.
Atlantic Antibodies, Westbrook, Maine.
Wellcome Reagents Ltd., Beckenham, England.
6 Hyland Laboratories, Costa Mesa, California.
Pharmacia Fine Chemicals, Inc., Piscataway, New Jersey.
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sought by use of double diffusion between serial di-
lutions of cryoprecipitate and antisera to titers of
I : 2048. In addition, low-concentration RID was
used to identify and quantitate trace amounts of
IgG, 1gM, IgA, Clq, C4, C2, C3c, C3d, factor B,
C3bINA, and /3H in the cryoprecipitate.
To ascertain whether cryoprecipitate contained
antigens not identified by anti-whole-human-serum
or the monospecific antisera tested, we produced
antiserum to triple-washed cryoprecipitate in rab-
bits: Purified cryoprecipitate (0.2 to 2.0 mg) in com-
plete Freund's adjuvant was injected into foodpads
or popliteal lymph nodes. Booster doses of 0.2 mg
of cryoprecipitate with adjuvant were used. The re-
sultant antiserum was used in double-diffusion,
IEP, and RID studies of cryoprecipitate and human
sera. This antiserum was additionally rendered
monospecific for a non-lgG y-migrating component
identified in the cryoprecipitate by adsorption with
insolubilized NHS [18].
To determine whether y heavy chains or i light
chains were responsible for C3 activation by our pa-
tient's cryoprecipitate, we insolubilized antisera to
y23 and K3 chains by glutaraldehyde linkage to
polyacrylamide beads [181. The cryoprecipitate was
incubated with the immunoadsorbents or with poly-
acrylamide beads alone for 1 hour at 37° C, and the
supernate was assayed for C3NeF activity and re-
sidual immunoglobulin. The antihuman y heavy
chain antisera used have been shown to react with
all four subclasses of lgG. The solid-phase heavy
chain-specific anti-y- and anti-K-chain adsorbents
used were capable of adsorbing 10 to 20 times the
amount of immunoglobulin present in an equal vol-
ume of cryoprecipitate solution.
To isolate and characterize the y components of
cryoprecipitate, we performed fractionation of cryo-
precipitate and serum on a 10% to 40% sucrose
gradient at x230,000g for 16 hours at 240 C in a
Beckman Model L5-75 ultracentrifuge with an
SW65 rotor (Beckman Instruments, Palo Alto, CA)
[19]. Gel chromatography was also performed on
serum and cryoprecipitate with G-200 Sephadex®
(Pharmacia Fine Chemicals, Piscataway, NJ), and
with a 0.5 M sodium chloride, 0.2 M phosphate buf-
fer (pH, 7.4) with azide, in a 2 >< 50-cm column at
24° C. Fractions were dialyzed against PBS (pH,
7.4) with azide and assayed for the presence of IgG,
f31H, the y-migrating component of the cryoprecipi-
tate, and C3 splitting activity as described above.
Renal tissue was obtained from the patient by
percutaneous renal biopsy, and portions were pro-
cessed for light and electron microscopy as pre-
viously reported [201. Tissue for immunopathologic
examination was processed as previously described
[21]. Antisera for direct immunofluorescence stud-
ies were fractionated with ammonium sulfate, and
the globulin fractions were conjugated with fluores-
cein isothiocyanate (FITC), isomer I (Baltimore Bi-
ological Laboratories, Baltimore, MD), with the
dialysis method [22, 231. Direct immuno-
fluorescence reagents used were FITC conjugated
monospecific antihuman (AH) IgG2'3'43, 1gM23'5,
lgA2'3'5, IgE3, K', y3 and IgG subgroups IgG2, IgG3,
and IgG4 prepared as previously reported [24]: AH
C1q3, C42, C21, C32'3, F4, B4, CS2, 1H1, C3bINA,
fibrinogen2, and a-macroglobulin2: and FITC con-
jugate of the antiserum rendered monospecific to
the y-migrating protein present in the cryoprecipi-
tate. Monospecificity of all antisera used was con-
firmed as previously described [21]. Immuno-
fluorescence staining techniques and controls were
performed as previously described [25]. Briefly, the
immunofluorescence staining characteristics of all
conjugates were assessed by examination of normal
kidney tissue substrates, examination of known
positive tissue specimens where possible, and
blocking of specific fluorescence by preincubation
of sections with unconjugated antisera.
Results
The protein concentration of purified precipitate,
when resuspended in a volume of PBS equal to the
original serum volume, ranged from 70 to 190 g/
ml. The solubilized cryoprecipitate, when diluted to
its original volume, caused in vitro conversion of
factor B to Bb and of C3 to C3c in NHS, Cl-depleted
or C2-deficient serum, and NHS with magnesium
EGTA added to 0.005 NI final concentration (Fig.
1). No activation of C3 occurred in factor-B-deplet-
ed serum or when EDTA was present throughout
the incubation. Solubilized cryoprecipitate induced
loss of 44% of C3 native-antigen present in NHS
with magnesium-EGTA. Control incubation with
PBS resulted in 14% loss of C3 B-antigen, whereas
incubation with zymosan led to 60% loss. Cryopre-
cipitate-induced C3 cleavage was 80% complete at
20 mm at 37° C and was unaffected by addition of
EDTA to 0.01 NI after 7 or 15 mm of incubation.
Incubation of the patient's own serum or plasma
samples alone at 4° C or 370 C caused no significant
conversion of C3 to C3c, or of factor B to Bb. C3
native-antigen concentration was unaffected by ei-
ther incubation or by warming of the 4° C aliquot to
Nonimmunoglobulin C3 activating .tactor 297
Fig. 1. C3 splitting assay. Fresh human serum before (upper
well) and after (lower well) incubation with cryoprecipitate. Im-
munoelectrophoresis against antihuman C3/C3c antiserum dem-
onstrates a change of C3 to the C3c position.
37° C for I hour to test for cold-induced C3 splitting
activity [151. Starting concentrations of C3 and fac-
tor B in our patient's sera, however, were less than
20% of normal values. The ability of the patient's
serum to activate C3 could be demonstrated at
37° C by the addition of NHS to the patient's fresh
serum sample or to serum incubated at 4° or 37° C
for 16 hours. Incubation of the patient's serum with
NHS at 4° C failed to cause C3 splitting, and mea-
surable C3 activation did not occur until the in-
cubation temperature was 32° C. Similar results
were obtained when a sample of human serum was
added to the patient's fresh plasma sample or to
plasma incubated at 4° C or 37° C for 16 hours.
Thus, there was no evidence to suggest that forma-
tion of the patient's C3 activating factor required in
vitro incubation in the cold [15]. C3 activation by
the patient's serum was mostly abolished by remov-
al of the cryoprecipitate. The cryoprecipitate's ac-
tivity was stable on heating at 54° to 56° C for 30
minutes, but was labile at 60° C.
In 1.5% agarose, no precipitin reactions were
produced between cryoprecipitate and antisera
monospecific to IgG, 1gM, IgA, IgE, Clq, Cls, C4,
C2, C3/C3c, C3d, CS, properdin, factor B, C3bINA,
X light chains, fibrinogen, a2-macroglobulin, or al-
bumin. Trace amounts of IgG were detected when
PEG-augmented gel diffusion was utilized.
Antiserum produced against the cryoprecipitate
identified three components. One component, of 'y
mobility on IEP, was identified by the antiserum to
cryoprecipitate and by no others (Fig. 2). This anti-
gen was not found in 75 cryoglobulins from patients
with immune complex diseases. It is distinct from
cold-insoluble globulin, as it could not be eluted by
warming of clots formed at 4° C [261. Separation of
this material from other components of the precipi-
tate by heating to 60° C correlated with loss of C3
splitting function. Low-titer RID with antiserum
monospecific for this y-migrating component of the
cryoprecipitate revealed that a small amount of this
material remained in the patient's serum supernates
after removal of cryoprecipitate. This material
could also be identified in trace, but varying,
amounts in all human sera tested. The material,
however, migrated in the ct. region in these latter
sera samples (Fig. 3). This a2 protein formed a pre-
cipitin line of complete identity with the y-migrating
protein in cryoprecipitate when tested by double
diffusion.
A second prominent y-/ band on IEP was identi-
fied by anticryoprecipitate and anti-whole-human-
Fig. 2. I,n,nunoelectrophoresis of crvoprecipitute and isolated
f31H (C3h inactis'ator—accelerotor). Top well: cryoprecipitate.
Bottom well: isolated H. The upper trough (T) and lower
trough (T3) contain anticryoprecipitate antiserum. The middle
trough (T2) contains monospecific antihuman /3H antiserum. A
gamma migrating component of the cryoprecipitate (—) is identi-
fied only by anticryoprecipitate antiserum. Antisera to 5H and
to cryoprecipitate identify /31H in the cryoprecipitate which mi-
grages in the gamma-beta region; isolated /IIH, identified by both
antisera, is confined to the usual beta region.
298 Bartlow et at
Fig. 3. Immunoelectrophoresis of human serum with anti-
cryoprecipitate antiserum. The upper trough contains antiserum
to cryoprecipitate. The lower trough contains anti-whole-human-
serum. The anticryoprecipitate forms a precipitin line with f31H() and with an a2 protein (4,) in the human serum.
serum. Antiserum monospecific for /31H globulin
showed complete identity with the other antisera
for this component (Fig. 2). The y portion of this
f31H arc on TEP represented f31H which was altered
in mobility. Incubation of the patient's fresh sample
of serum at 4° C resulted in development of this al-
tered /31H mobility, whereas serum depleted of
cryoprecipitate contained only normally migrating
f31H. No similar change occurred during incubation
at 37° C.
Trace amounts of K light chains were identified in
the cryoprecipitate by anticryoprecipitate and anti-
K-chain antisera. Immunoelectrophoresis and
double-diffusion of cryoprecipitate in PEG-aug-
mented gel against anti-IgG (y heavy chain) anti-
sera23'4 produced a 'y precipitin band which showed
nonidentity with /31H and the cryoprecipitate's y
component. Immunoglobulin G was present in con-
centrations of 5 to 14 g/ml in various cryoprecipi-
tates. Immunoadsorption of cryoprecipitate with
antihuman K or y chain antisera insolubilized on
polyacrylamide beads removed all identifiable im-
munoglobulin light- and heavy-chain components,
but caused no loss of C3 splitting activity compared
with comparably treated aliquots of cryoprecipitate
mixed with inactivated, swollen polyacrylamide
beads.
Dr. Enrique Vallota and Ms. Judith Forristal, Children's Hos-
pital Research Foundation, Cincinnati, Ohio, made the initial
identification of the j31H component.
No other proteins of normal human serum or
plasma were detected by anticryoprecipitate or any
of the other antisera tested in standard or in PEG-
augmented gels. Furthermore, anticryoprecipitate
formed no precipitin with functionally pure human
C39 at dilutions of either antibody or antigen from
neat to 1: 2048 in either gel. This C3 preparation
formed precipitins in gel with anti-C32 over a wide
range of concentrations.
When cryoprecipitate was fractionated on a 10%
to 40% sucrose density gradient, the y component
was antigenically present in 20 to 24s fractions
which contained no IgG or /31H by low-titer RID or
PEG-augmented double diffusion. Immunoelectro-
phoresis of the 20 to 24s fractions revealed that the
y component of cryoprecipitate now migrated in the
a2 region. C3 splitting activity was confined to these
fractions; 7s and fractions containing J31H demon-
strated no such activity. The a2 protein identified in
serum could not be identified in sucrose density gra-
dient fractions of serum, presumably as a result of
its low concentrations in serum. On G-200 Seph-
adex®, both the y component of cryoprecipitate
and the a2 component of serum eluted in the void
volume.
In the renal biopsy there was diffuse glomerular
mesangial expansion and endocapillary prolifera-
tion with complex duplication of the glomerular
basement membranes (Fig. 4A). Electron micros-
copy showed predominantly subendothelial and
mesangial electron-dense deposits with focal sub-
epithelial extensions (Fig. 4B). Direct immuno-
fluorescence of the renal biopsy gave negative re-
sults for IgG, 1gM, IgA, IgE, IgG2, IgG3, IgG4, K
chains, y chains, Clq, C4, C2, factor B, fibrinogen,
C3bINA, and a-2-macroglobulin. Staining for C3
gave intense granular fluorescence of glomerular
mesangium and capillary loops (Fig. 5). Fluores-
cence for properdin and C5 was present in the same
distribution as for C3, but was less intense. Staining
for $1H and for the gamma migrating protein pres-
ent in the cryoprecipitate gave intense granular flu-
orescence in the same distribution as anti-C3 did
(Fig. 6). Blocking studies with unlabeled mono-
specific anti-f31H and antibody to the y-migrating
component of cryoprecipitate completely abolished
positive fluorescence for B1H and the y-migrating
protein, respectively. Blocking with unlabeled anti-
IgG, and anti-K chain antisera did not alter staining
for f31H. Blocking with unlabeled AH IgG, -K chain,
Cordis Laboratories, Miami, Florida.
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-y chain, and -f31H antisera did not change positive
staining for the y-migrating protein present in the
cryoprecipitate.
Discussion
Our patient's cryoprecipitate contains a C3 acti-
vating factor (C3AF) which fulfills the functional
criteria which currently define a C3NeF. It acti-
vates complement through the alternative pathway,
utilizing factor B and magnesium ions but not Cl,
C2, or calcium ions [9, 10, 16]. It is thermostable at
54° to 56° C but labile at 60° C [10]. Unlike most C3
nephritic factors studied by immunoadsorption [6-8]
or ultracentrifugation [27], our patient's C3AF ac-
tivity does not appear to be attributable to IgG,
since removal of all identifiable IgG light and heavy
chain determinants did not affect the C3AF activity.
This C3 splitting activity appears to be a function of
the y-migrating component of our patient's cryopre-
cipitates.
The presence of a serum a2 protein which was
identified by antisera to the y-migrating component
of the cryoprecipitate suggests that this C3AF may
be an altered or activated form of a normal serum
component. The 20 to 24s C3AF fractions isolated
by sucrose gradient ultracentifugation indicate a
high molecular weight for this factor, suggesting
that the y-migrating material might be altered by ag-
gregation. Since we have been unable to estimate
the molecular weight of the a2 component in serum,
because of its low concentration and subsequent di-
lution in sucrose gradients, our ultracentrifugation
studies do not clarify this possibility. Gel chroma-
tography results, however, suggest that both the a2
protein and the y component of cryoprecipitate
have high molecular weights. High molecular-
weight C3 splitting factors have been described in
the serum of patients with systemic lupus erythema-
tosus [28]. These factors, however, were shown to
contain large quantities of immunoglobulins, and
adsorption of these immunoglobulins removed the
C3 splitting activity.
Cold-inducible C3 splitting activity has been de-
scribed in glomerulonephritis and cirrhosis [14, 151.
Incubation of such sera in the cold induced C3
cleavage via the alternative complement pathway.
C3 cleavage did not occur in our patient's serum or
plasma at 4° C. When mixed with fresh NHS, her
C3AF functioned optimally at 37° C, poorly at
32° C, and not at all at 4° C. C3 reportedly can be
aggregated by prolonged cooling or freezing, result-
ing in C3 splitting activity [29]. The failure of anti-
human C3 to react with cryoprecipitate, or of anti-
cryoprecipitate to react with isolated C3 makes it
Fig. 4. Renal biopsy glonierular histology and electron microscopy. A This representative glomerulus has a lobular pattern with mesangi-
al hypercellularity and an increase in mesangial matrix. Many capillary loops contain prominent hyaline intracapillary deposits (*)
between double contours of the basement membrane. (Methenamine silver-PAS stain; original magnification, X 100) B The glomerular
capillary wall contains a prominent subendothelial deposit (D). Asterisk (*) denotes original basement membrane, C, the capillary lumen,
and tilC, the mesangial cell process. (Uranylacetate and lead citrate stain; original magnification, x4000.)
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unlikely that our patient's C3AF is aggregated C3 or
IgG bound to a C3-containing C3 convertase [6, 27].
Beta-i-H globulin was a major component of our
patient's cryoprecipitate. This protein has been
demonstrated to be a crucial cofactor for the activi-
ty of C3bINA 130, 311. C3b inactivator limits com-
plement activation by enzymatically destroying free
C3b and C3b present in C3 convertases of the clas-
sical pathway, the alternative pathway, and the C3b
feedback loop [32]. Beta-i-H globulin appears to
render C4b and C3b in these convertases suscep-
tible to inactivation by C3bINA [311. C3b in-
activator is ineffective in the absence of 31H,
whereas f31H alone will increase the rate of decay of
C3b-containing convertases, apparently by dis-
placing Bb [33]. Minimal reductions in levels or
function of/31H or C3bINA can result in spontane-
ous alternative complement pathway activation [34,
351.
The association of the C3AF which we describe
with /31H globulin in a cryoprecipitate, and the de-
velopment of altered f31H electrophoretic mobility
on incubation of our patient's serum at 4° C may
reflect fluid phase interaction between these com-
ponents. Interaction between f31H and the C3AF
component could affect the electrophoretic mobility
of each. Functionally, inhibition of/31H by this ma-
Fig. 5. Photornicrograph of glorn era/or ,mmunofluorescenee for
C3. C3 is present in a coarse granular pattern along the glomeru-
lar capillary loops and in the mesangium. (Rabbit AH C3, FITC;
original magnification. x 100.)
Fig. 6. Photomicrographs at glomerular im,nunofluoreccer,ce for
the y—migrating protein of cryoprecipitote and for f31H globulin.
A Antiserum rendered monspecific for the y-migrating protein of
cryoprecipitate stains glomerular capillary loops and the mesan-
gium in a coarse granular pattern. (Rabbit AH cryoprecipitate y
protein, FITC; original magnification, x63) B Beta-I-H is pres-
ent in a coarse granular pattern along glomerular capillary loops
and in the mesangium. (Goat AH H, FITC; original magnifica-
tion, x63.)
terial could result in release of the alternative com-
plement pathway from its normal control by f3LH
and C3bINA, thus resulting in C3 activation. A sim-
ilar functional role has been reported for one
C3NeF which appeared to limit access of 1H or
C3bINA to cell-bound C3 convertases [361. Con-
vertase half-life was thereby prolonged, causing lo-
cal complement activation and C3 deposition [36,
371.
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This is the first report of glomerular localization
of a nonimmunoglobulin alternative complement
pathway C3 activating factor. Immunopathologic
examination demonstrated glomerular deposition of
the 'y-migrating C3 activating factor which was pres-
ent in serum and in cryoprecipitate. Beta-I-H and
C3 were present in a distribution identical to that of
the y protein.
The role of C3 activating or nephritic" factors in
the pathogenesis of MPGN remains unclear [38-401.
Levy et at [40] have observed that some patients
with MPGN and subendothelial deposits (type I)
have glomerular deposits of C3 alone, but in others
IgG, Clq, and C4 are also present. This suggests
that the pathogenesis of glomerular injury in some
patients with type I MPGN is due primarily to alter-
native complement pathway activation, as has been
suggested for type II MPGN (dense deposit dis-
ease). Our patient's serum complement levels and
immunopathology are suggestive of alternative
complement pathway C3 activation without in-
volvement of the classic pathway. We suggest that
the gamma-migrating protein identified in this pa-
tient binds j31H and functionally inactivates this vi-
tat complement regulatory protein. The interaction
of the C3AF with J3IH in the glomerulus in this case
could locally release the alternative complement
pathway from its normal inhibition by /31H and
C3bINA. This would tend to stabilize C3 convert-
ases, thus leading to C3 deposition and com-
plement-mediated glomerular damage.
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